Moderna, Inc. (NASDAQ: MRNA) has unveiled plans to share insights from its extensive respiratory portfolio, encompassing vaccines and vaccine candidates targeting COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data pertaining to its latent virus portfolio concerning cytomegalovirus (CMV), at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain, taking place from April 27-30, 2024.
During the ESCMID Global Congress, Moderna is scheduled to deliver nine presentations, featuring two late-breaker oral presentations, two oral presentations, and five poster presentations:
COVID-19
P0422: Demonstrating CD4+ T-cell responses in solid organ transplant recipients induced by the mRNA-1273 COVID-19 vaccine Presenter: Bethany Girard P0553: Conducting a systematic literature review and meta-analysis using the GRADE framework to compare the effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults Presenter: Ekkehard Beck OS104: Assessing the safety and immunogenicity of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine Presenter: Spyros Chalkias OS262: Analyzing the demographic diversity of participants in infectious disease vaccine clinical trials Presenter: Jameka Hill Influenza
P0109: Presenting Phase 1/2 trial findings of next-generation mRNA-based seasonal influenza vaccines, including additional A/H3N2 strains, in adults aged 50 to 75 years Presenter: Denise Hsu P0088: Discussing consumer preferences for features of influenza vaccines in the United Kingdom through results from a discrete-choice experiment study Presenter: Deborah Rudin OS235: Evaluating the safety and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults Presenter: Mieke Soens Respiratory Syncytial Virus (RSV)
OS102: Investigating the coadministration of a respiratory syncytial virus vaccine (mRNA-1345) with an influenza or SARS-CoV-2 vaccine in older adults Presenter: Jaya Goswami Cytomegalovirus (CMV)
P0180: Exploring potential relationships between cytomegalovirus and immunosenescence through evidence from observational studies Presenter: John Diaz-DeCarlo
Moderna is a pioneering force in mRNA medicine, revolutionizing the landscape of pharmaceuticals through the advancement of mRNA technology. Over the past decade, Moderna has harnessed this technology to accelerate the development of medicines with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
The mRNA platform developed by Moderna has facilitated the creation of therapeutics and vaccines for various infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a global team united by Moderna’s values and committed to reshaping the future of human health, the company endeavors to maximize the impact of mRNA medicines on people’s lives. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Moderna disclaims any intention or responsibility to update or revise any forward-looking statements in this press release. These statements are based on Moderna’s current expectations and speak only as of the date of this press release.
